| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gaucher Disease | 46 | 2022 | 60 | 11.680 |
Why?
|
| Glucosylceramidase | 39 | 2022 | 50 | 8.130 |
Why?
|
| Saposins | 20 | 2020 | 24 | 3.940 |
Why?
|
| Glucosylceramides | 22 | 2019 | 32 | 3.210 |
Why?
|
| Orthopedics | 5 | 2021 | 88 | 1.990 |
Why?
|
| Disease Models, Animal | 32 | 2020 | 2550 | 1.880 |
Why?
|
| Glycosphingolipids | 10 | 2017 | 51 | 1.660 |
Why?
|
| Cervical Vertebrae | 3 | 2020 | 86 | 1.630 |
Why?
|
| Psychosine | 7 | 2016 | 33 | 1.480 |
Why?
|
| Orthopedic Procedures | 4 | 2020 | 102 | 1.460 |
Why?
|
| Mice | 48 | 2022 | 8474 | 1.340 |
Why?
|
| Lysosomes | 11 | 2022 | 136 | 1.170 |
Why?
|
| Animals | 56 | 2022 | 20881 | 1.020 |
Why?
|
| Neurons | 10 | 2021 | 881 | 0.980 |
Why?
|
| Brain | 14 | 2022 | 2176 | 0.980 |
Why?
|
| beta-Glucosidase | 4 | 2019 | 7 | 0.930 |
Why?
|
| Imino Pyranoses | 3 | 2015 | 4 | 0.920 |
Why?
|
| Phenotype | 16 | 2019 | 947 | 0.920 |
Why?
|
| Central Nervous System | 6 | 2016 | 107 | 0.880 |
Why?
|
| Internship and Residency | 4 | 2021 | 596 | 0.820 |
Why?
|
| Mice, Knockout | 19 | 2022 | 1692 | 0.810 |
Why?
|
| Correspondence as Topic | 1 | 2021 | 5 | 0.790 |
Why?
|
| Personnel Selection | 1 | 2021 | 37 | 0.760 |
Why?
|
| Spinal Injuries | 1 | 2020 | 30 | 0.720 |
Why?
|
| Nervous System Diseases | 2 | 2013 | 142 | 0.720 |
Why?
|
| Epidural Abscess | 1 | 2019 | 1 | 0.700 |
Why?
|
| Clostridium septicum | 1 | 2019 | 5 | 0.700 |
Why?
|
| Injury Severity Score | 1 | 2020 | 204 | 0.700 |
Why?
|
| Educational Measurement | 1 | 2021 | 254 | 0.680 |
Why?
|
| Neural Stem Cells | 2 | 2019 | 32 | 0.670 |
Why?
|
| Clostridium Infections | 1 | 2019 | 52 | 0.660 |
Why?
|
| Inflammation | 5 | 2018 | 1030 | 0.640 |
Why?
|
| Lysosomal Storage Diseases | 3 | 2018 | 6 | 0.610 |
Why?
|
| Lysosome-Associated Membrane Glycoproteins | 2 | 2014 | 6 | 0.610 |
Why?
|
| Gene Expression Profiling | 3 | 2015 | 498 | 0.610 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2019 | 86 | 0.610 |
Why?
|
| Spondylosis | 1 | 2017 | 3 | 0.600 |
Why?
|
| Spinal Stenosis | 1 | 2017 | 12 | 0.600 |
Why?
|
| Mitochondria | 4 | 2021 | 643 | 0.590 |
Why?
|
| Mutation | 10 | 2022 | 1213 | 0.580 |
Why?
|
| Glycoproteins | 3 | 2003 | 238 | 0.580 |
Why?
|
| Humans | 50 | 2021 | 68618 | 0.570 |
Why?
|
| Glucosyltransferases | 5 | 2017 | 28 | 0.570 |
Why?
|
| Autophagy | 2 | 2021 | 208 | 0.550 |
Why?
|
| Neurodegenerative Diseases | 3 | 2014 | 102 | 0.540 |
Why?
|
| Fibroblasts | 5 | 2015 | 902 | 0.530 |
Why?
|
| Mutation, Missense | 3 | 2013 | 112 | 0.520 |
Why?
|
| Complement System Proteins | 1 | 2017 | 135 | 0.520 |
Why?
|
| Lung | 4 | 2014 | 849 | 0.510 |
Why?
|
| Spinal Diseases | 2 | 2013 | 53 | 0.510 |
Why?
|
| Amino Acid Substitution | 6 | 2014 | 137 | 0.510 |
Why?
|
| Inositol | 5 | 2016 | 11 | 0.510 |
Why?
|
| RNA, Messenger | 4 | 2015 | 1664 | 0.500 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 320 | 0.500 |
Why?
|
| Receptors, Scavenger | 1 | 2014 | 13 | 0.490 |
Why?
|
| Wolman Disease | 1 | 2014 | 1 | 0.480 |
Why?
|
| Phagosomes | 2 | 2013 | 19 | 0.470 |
Why?
|
| alpha-Synuclein | 5 | 2016 | 28 | 0.470 |
Why?
|
| School Admission Criteria | 1 | 2013 | 36 | 0.450 |
Why?
|
| Immune Evasion | 1 | 2013 | 19 | 0.450 |
Why?
|
| Ceramides | 5 | 2013 | 578 | 0.440 |
Why?
|
| Lymph Nodes | 1 | 2014 | 258 | 0.440 |
Why?
|
| Organ Specificity | 5 | 2017 | 167 | 0.430 |
Why?
|
| Ilium | 1 | 2013 | 16 | 0.430 |
Why?
|
| Bone Substitutes | 1 | 2013 | 20 | 0.430 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 214 | 0.430 |
Why?
|
| Mutant Proteins | 2 | 2010 | 45 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 504 | 0.430 |
Why?
|
| Chemokines | 1 | 2013 | 119 | 0.430 |
Why?
|
| Bone Transplantation | 1 | 2013 | 43 | 0.420 |
Why?
|
| Fellowships and Scholarships | 1 | 2013 | 127 | 0.420 |
Why?
|
| Liver | 8 | 2018 | 1118 | 0.410 |
Why?
|
| Enzyme Therapy | 1 | 2012 | 4 | 0.410 |
Why?
|
| Transcriptome | 1 | 2013 | 164 | 0.400 |
Why?
|
| Vertebral Artery | 1 | 2011 | 22 | 0.400 |
Why?
|
| Spleen | 5 | 2014 | 301 | 0.390 |
Why?
|
| Vascular System Injuries | 1 | 2011 | 20 | 0.390 |
Why?
|
| Cells, Cultured | 9 | 2015 | 2673 | 0.380 |
Why?
|
| Mice, Transgenic | 8 | 2020 | 1033 | 0.380 |
Why?
|
| Intraoperative Complications | 1 | 2011 | 129 | 0.370 |
Why?
|
| Aging | 2 | 2016 | 911 | 0.370 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 1293 | 0.370 |
Why?
|
| Male | 19 | 2021 | 37321 | 0.360 |
Why?
|
| Gangliosides | 1 | 2010 | 29 | 0.360 |
Why?
|
| Esophagus | 1 | 2011 | 303 | 0.350 |
Why?
|
| Calcium Channels, L-Type | 1 | 2009 | 34 | 0.340 |
Why?
|
| Postoperative Complications | 1 | 2017 | 1615 | 0.340 |
Why?
|
| HIV Infections | 1 | 2017 | 791 | 0.340 |
Why?
|
| Asparagine | 1 | 2009 | 15 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 2791 | 0.330 |
Why?
|
| Spinal Fusion | 3 | 2017 | 90 | 0.330 |
Why?
|
| Biocatalysis | 1 | 2009 | 23 | 0.330 |
Why?
|
| Calcium Channel Blockers | 1 | 2009 | 138 | 0.330 |
Why?
|
| Glutamine | 1 | 2009 | 45 | 0.320 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2021 | 118 | 0.320 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2008 | 6 | 0.320 |
Why?
|
| Lipids | 5 | 2014 | 298 | 0.320 |
Why?
|
| Female | 20 | 2021 | 38074 | 0.320 |
Why?
|
| Enzyme Replacement Therapy | 4 | 2020 | 7 | 0.310 |
Why?
|
| Brain Diseases | 1 | 2008 | 78 | 0.300 |
Why?
|
| Genes, Regulator | 2 | 2008 | 17 | 0.300 |
Why?
|
| Models, Biological | 5 | 2014 | 981 | 0.300 |
Why?
|
| Complement C5a | 2 | 2018 | 15 | 0.300 |
Why?
|
| Enzyme Inhibitors | 4 | 2016 | 659 | 0.290 |
Why?
|
| Catalytic Domain | 4 | 2011 | 99 | 0.290 |
Why?
|
| Spinal Cord | 1 | 2008 | 244 | 0.280 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2014 | 618 | 0.280 |
Why?
|
| Viscera | 1 | 2006 | 16 | 0.280 |
Why?
|
| Sterol Esterase | 2 | 2018 | 5 | 0.280 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2018 | 146 | 0.270 |
Why?
|
| T-Lymphocytes | 3 | 2017 | 597 | 0.270 |
Why?
|
| United States | 5 | 2021 | 7367 | 0.270 |
Why?
|
| Phosphatidylserines | 2 | 2020 | 22 | 0.260 |
Why?
|
| Protein Kinase C | 3 | 2009 | 270 | 0.260 |
Why?
|
| Point Mutation | 4 | 2008 | 97 | 0.260 |
Why?
|
| Parkinson Disease | 2 | 2022 | 272 | 0.250 |
Why?
|
| Gene Expression | 1 | 2006 | 770 | 0.230 |
Why?
|
| Up-Regulation | 4 | 2018 | 682 | 0.220 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2014 | 114 | 0.220 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 134 | 0.220 |
Why?
|
| Protein Transport | 3 | 2016 | 280 | 0.210 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 282 | 0.210 |
Why?
|
| Cell Cycle | 2 | 2014 | 312 | 0.210 |
Why?
|
| Nerve Degeneration | 2 | 2015 | 134 | 0.210 |
Why?
|
| Macrophages | 3 | 2014 | 647 | 0.200 |
Why?
|
| Longevity | 2 | 2014 | 60 | 0.200 |
Why?
|
| Hippocampus | 2 | 2016 | 471 | 0.200 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2021 | 7 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 710 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2020 | 7029 | 0.190 |
Why?
|
| Reference Standards | 1 | 2021 | 115 | 0.190 |
Why?
|
| Enzyme Stability | 2 | 2011 | 30 | 0.190 |
Why?
|
| Hydrolysis | 3 | 2009 | 144 | 0.190 |
Why?
|
| Receptor, Anaphylatoxin C5a | 2 | 2018 | 20 | 0.180 |
Why?
|
| Keloid | 1 | 2020 | 10 | 0.180 |
Why?
|
| Disease Progression | 3 | 2016 | 1038 | 0.180 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 132 | 0.180 |
Why?
|
| Enzyme Activation | 4 | 2016 | 791 | 0.180 |
Why?
|
| Cicatrix | 1 | 2020 | 60 | 0.170 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 99 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 329 | 0.170 |
Why?
|
| Low Back Pain | 1 | 2019 | 45 | 0.170 |
Why?
|
| Drug Delivery Systems | 2 | 2020 | 236 | 0.170 |
Why?
|
| Purkinje Cells | 2 | 2009 | 18 | 0.170 |
Why?
|
| DNA Primers | 3 | 2004 | 302 | 0.160 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 481 | 0.160 |
Why?
|
| Genotype | 3 | 2016 | 786 | 0.160 |
Why?
|
| Cytokines | 2 | 2017 | 866 | 0.160 |
Why?
|
| Homozygote | 2 | 2009 | 119 | 0.160 |
Why?
|
| Glycolipids | 2 | 2016 | 20 | 0.160 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 2 | 2015 | 19 | 0.160 |
Why?
|
| Cholesterol | 2 | 2018 | 331 | 0.160 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2018 | 3 | 0.160 |
Why?
|
| Macrophages, Peritoneal | 1 | 2018 | 67 | 0.150 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2018 | 29 | 0.150 |
Why?
|
| Adult | 6 | 2021 | 21403 | 0.150 |
Why?
|
| Total Disc Replacement | 1 | 2017 | 1 | 0.150 |
Why?
|
| Autoantibodies | 2 | 2018 | 434 | 0.150 |
Why?
|
| Neoplasms | 1 | 2009 | 1667 | 0.150 |
Why?
|
| Diskectomy | 1 | 2017 | 12 | 0.150 |
Why?
|
| Base Sequence | 3 | 2004 | 1015 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 3 | 2003 | 492 | 0.150 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 1083 | 0.150 |
Why?
|
| Motor Activity | 2 | 2013 | 621 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 18 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.140 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 1447 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2011 | 1200 | 0.140 |
Why?
|
| Antigen-Presenting Cells | 1 | 2017 | 50 | 0.140 |
Why?
|
| Dantrolene | 1 | 2016 | 8 | 0.140 |
Why?
|
| Cell Line | 5 | 2018 | 1752 | 0.140 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 200 | 0.140 |
Why?
|
| Mice, Mutant Strains | 2 | 2015 | 166 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2010 | 284 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 3259 | 0.140 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 103 | 0.140 |
Why?
|
| Quinuclidines | 1 | 2016 | 10 | 0.130 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2016 | 56 | 0.130 |
Why?
|
| Kidney | 2 | 2013 | 945 | 0.130 |
Why?
|
| Carbamates | 1 | 2016 | 41 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.130 |
Why?
|
| Hair Cells, Ampulla | 1 | 2015 | 1 | 0.130 |
Why?
|
| Complement Activation | 1 | 2017 | 145 | 0.130 |
Why?
|
| Vestibule, Labyrinth | 1 | 2015 | 19 | 0.130 |
Why?
|
| Vestibular Diseases | 1 | 2015 | 11 | 0.130 |
Why?
|
| Memory Disorders | 1 | 2016 | 111 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 333 | 0.130 |
Why?
|
| Satellite Cells, Perineuronal | 1 | 2015 | 1 | 0.130 |
Why?
|
| Leukodystrophy, Metachromatic | 1 | 2015 | 2 | 0.130 |
Why?
|
| Transfection | 2 | 2014 | 782 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 81 | 0.120 |
Why?
|
| Neurogenesis | 1 | 2015 | 32 | 0.120 |
Why?
|
| Hearing Disorders | 1 | 2015 | 23 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2077 | 0.120 |
Why?
|
| Spiral Ganglion | 1 | 2015 | 47 | 0.120 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 306 | 0.120 |
Why?
|
| Membrane Potentials | 1 | 2015 | 200 | 0.120 |
Why?
|
| Chromatography, Liquid | 2 | 2017 | 120 | 0.120 |
Why?
|
| Mutagenesis | 1 | 2014 | 60 | 0.120 |
Why?
|
| Alanine | 1 | 2014 | 38 | 0.120 |
Why?
|
| Binding, Competitive | 1 | 2014 | 165 | 0.120 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 77 | 0.120 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 42 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2014 | 89 | 0.120 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2014 | 13 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 410 | 0.120 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2014 | 73 | 0.110 |
Why?
|
| Organ Size | 1 | 2014 | 242 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 322 | 0.110 |
Why?
|
| Amines | 1 | 2014 | 98 | 0.110 |
Why?
|
| Epidermis | 1 | 2013 | 42 | 0.110 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 742 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 81 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2014 | 115 | 0.110 |
Why?
|
| Substantia Nigra | 1 | 2014 | 102 | 0.110 |
Why?
|
| Sequestosome-1 Protein | 1 | 2013 | 12 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 113 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 122 | 0.110 |
Why?
|
| Galactosylceramidase | 1 | 2013 | 11 | 0.110 |
Why?
|
| Brain Stem | 1 | 2013 | 46 | 0.110 |
Why?
|
| Bone Matrix | 1 | 2013 | 8 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 186 | 0.110 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 69 | 0.110 |
Why?
|
| Bone Regeneration | 1 | 2013 | 20 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 120 | 0.110 |
Why?
|
| beta-Galactosidase | 1 | 2013 | 88 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2013 | 168 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 1174 | 0.110 |
Why?
|
| Athletes | 1 | 2013 | 40 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2013 | 57 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2013 | 239 | 0.110 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 415 | 0.110 |
Why?
|
| Hearing Loss | 1 | 2015 | 154 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 145 | 0.100 |
Why?
|
| Neutrophils | 1 | 2013 | 204 | 0.100 |
Why?
|
| Models, Molecular | 1 | 2014 | 546 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2013 | 392 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1174 | 0.100 |
Why?
|
| Antigens, CD1 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 242 | 0.100 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 215 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2015 | 330 | 0.100 |
Why?
|
| Aged | 3 | 2019 | 14862 | 0.100 |
Why?
|
| Corpus Striatum | 1 | 2014 | 279 | 0.100 |
Why?
|
| Hematology | 1 | 2012 | 10 | 0.100 |
Why?
|
| Body Weight | 1 | 2014 | 554 | 0.100 |
Why?
|
| Molecular Biology | 1 | 2012 | 31 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 214 | 0.100 |
Why?
|
| Atlanto-Axial Joint | 1 | 2011 | 13 | 0.100 |
Why?
|
| Behavior, Animal | 2 | 2016 | 470 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2013 | 201 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 125 | 0.100 |
Why?
|
| Protein Binding | 1 | 2014 | 1027 | 0.100 |
Why?
|
| Substrate Specificity | 2 | 2009 | 234 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 329 | 0.100 |
Why?
|
| Peptides | 1 | 2014 | 455 | 0.100 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 55 | 0.100 |
Why?
|
| Glycoside Hydrolases | 1 | 2011 | 25 | 0.100 |
Why?
|
| Lewy Body Disease | 1 | 2011 | 9 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 626 | 0.100 |
Why?
|
| Pyrrolidines | 2 | 2010 | 45 | 0.090 |
Why?
|
| Arteries | 1 | 2011 | 108 | 0.090 |
Why?
|
| Incidence | 2 | 2013 | 1603 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 2223 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2012 | 155 | 0.090 |
Why?
|
| Cell Movement | 1 | 2013 | 630 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2020 | 2007 | 0.090 |
Why?
|
| Skin | 2 | 2013 | 451 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 447 | 0.090 |
Why?
|
| Adolescent | 2 | 2014 | 8912 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 181 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 73 | 0.090 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2010 | 4 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 507 | 0.090 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 82 | 0.090 |
Why?
|
| Protein Folding | 1 | 2010 | 82 | 0.090 |
Why?
|
| Antibody Formation | 1 | 2010 | 93 | 0.090 |
Why?
|
| Verapamil | 1 | 2009 | 30 | 0.090 |
Why?
|
| Diltiazem | 1 | 2009 | 26 | 0.090 |
Why?
|
| Long-Term Potentiation | 1 | 2010 | 53 | 0.090 |
Why?
|
| Jews | 1 | 2009 | 7 | 0.080 |
Why?
|
| Interleukin-8 | 1 | 2009 | 71 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 159 | 0.080 |
Why?
|
| Taurocholic Acid | 1 | 2009 | 2 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2009 | 11 | 0.080 |
Why?
|
| 2,4-Dinitrophenol | 1 | 2009 | 6 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 13 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 1536 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2009 | 25 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 951 | 0.080 |
Why?
|
| Selection, Genetic | 1 | 2009 | 49 | 0.080 |
Why?
|
| Alleles | 2 | 2016 | 386 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2021 | 7277 | 0.080 |
Why?
|
| Azides | 1 | 2009 | 56 | 0.080 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 101 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 284 | 0.080 |
Why?
|
| Neuroprotective Agents | 2 | 2016 | 317 | 0.080 |
Why?
|
| Molecular Structure | 1 | 2010 | 397 | 0.080 |
Why?
|
| Biological Transport | 2 | 2020 | 210 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 160 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 49 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2009 | 110 | 0.080 |
Why?
|
| Cerebrum | 1 | 2008 | 20 | 0.080 |
Why?
|
| Glycosylation | 1 | 2009 | 185 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 217 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2008 | 63 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 2009 | 92 | 0.080 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 420 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2008 | 219 | 0.080 |
Why?
|
| Keratinocytes | 1 | 2008 | 68 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 244 | 0.070 |
Why?
|
| Risk | 1 | 2009 | 563 | 0.070 |
Why?
|
| Cerebellum | 1 | 2008 | 103 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 615 | 0.070 |
Why?
|
| Myelin Basic Protein | 1 | 2007 | 62 | 0.070 |
Why?
|
| Pandemics | 2 | 2021 | 352 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2008 | 447 | 0.070 |
Why?
|
| Age Factors | 2 | 2008 | 1864 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 232 | 0.070 |
Why?
|
| Doxycycline | 1 | 2006 | 49 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2005 | 282 | 0.070 |
Why?
|
| Registries | 1 | 2009 | 733 | 0.060 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 60 | 0.060 |
Why?
|
| Transgenes | 1 | 2005 | 92 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 786 | 0.060 |
Why?
|
| Thymus Gland | 1 | 2005 | 97 | 0.060 |
Why?
|
| Child | 2 | 2009 | 6405 | 0.060 |
Why?
|
| Acoustic Stimulation | 2 | 2016 | 206 | 0.060 |
Why?
|
| Biomarkers | 2 | 2018 | 1593 | 0.060 |
Why?
|
| Hearing Tests | 2 | 2015 | 70 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1641 | 0.060 |
Why?
|
| Prevalence | 1 | 2009 | 1619 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1745 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2003 | 189 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2017 | 139 | 0.060 |
Why?
|
| 5' Flanking Region | 1 | 2003 | 8 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2003 | 19 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2003 | 47 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2016 | 282 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2003 | 191 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 272 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2003 | 114 | 0.050 |
Why?
|
| Antibodies | 1 | 2003 | 241 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2324 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 32 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2015 | 2689 | 0.050 |
Why?
|
| CHO Cells | 2 | 2012 | 161 | 0.050 |
Why?
|
| Cricetinae | 2 | 2012 | 262 | 0.050 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2020 | 13 | 0.050 |
Why?
|
| Drug Stability | 1 | 2020 | 71 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2020 | 54 | 0.040 |
Why?
|
| Middle Aged | 3 | 2016 | 21147 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 86 | 0.040 |
Why?
|
| Integrin alpha4beta1 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Permeability | 1 | 2020 | 131 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2019 | 35 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 334 | 0.040 |
Why?
|
| Nanostructures | 1 | 2020 | 112 | 0.040 |
Why?
|
| Carcinogens | 2 | 2009 | 86 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2009 | 138 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 277 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2009 | 137 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2020 | 213 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 222 | 0.040 |
Why?
|
| Liposomes | 2 | 2012 | 107 | 0.040 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Chitinases | 1 | 2018 | 1 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 2018 | 29 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 714 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2018 | 44 | 0.040 |
Why?
|
| Feces | 1 | 2018 | 88 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 948 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2017 | 67 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 434 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2018 | 161 | 0.040 |
Why?
|
| Workload | 1 | 2018 | 103 | 0.040 |
Why?
|
| Spatial Memory | 1 | 2016 | 9 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2009 | 954 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2016 | 207 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2016 | 97 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2016 | 79 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2003 | 3187 | 0.030 |
Why?
|
| Encephalitis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Gait | 1 | 2016 | 120 | 0.030 |
Why?
|
| Fear | 1 | 2016 | 239 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 30 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 248 | 0.030 |
Why?
|
| Swimming | 1 | 2015 | 38 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.030 |
Why?
|
| Ileum | 1 | 2014 | 28 | 0.030 |
Why?
|
| Neuroglia | 1 | 2015 | 136 | 0.030 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2015 | 49 | 0.030 |
Why?
|
| Cecum | 1 | 2014 | 39 | 0.030 |
Why?
|
| Organoids | 1 | 2014 | 42 | 0.030 |
Why?
|
| Time Factors | 1 | 2003 | 4655 | 0.030 |
Why?
|
| Axons | 1 | 2015 | 139 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 138 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2014 | 9 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 238 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 1851 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 329 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2013 | 52 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 236 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 230 | 0.030 |
Why?
|
| Cochlea | 1 | 2015 | 169 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2015 | 240 | 0.030 |
Why?
|
| Metformin | 1 | 2014 | 63 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 122 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 765 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 627 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 254 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2800 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1266 | 0.030 |
Why?
|
| DNA | 1 | 2015 | 597 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 326 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.030 |
Why?
|
| Global Health | 1 | 2013 | 136 | 0.030 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2012 | 32 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2012 | 24 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 94 | 0.020 |
Why?
|
| Cathepsin D | 1 | 2011 | 13 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2279 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 38 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2014 | 219 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 204 | 0.020 |
Why?
|
| Calnexin | 1 | 2010 | 1 | 0.020 |
Why?
|
| Calreticulin | 1 | 2010 | 3 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2010 | 10 | 0.020 |
Why?
|
| Detergents | 1 | 2010 | 34 | 0.020 |
Why?
|
| Vimentin | 1 | 2010 | 47 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 118 | 0.020 |
Why?
|
| Solubility | 1 | 2010 | 134 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3705 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 98 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 371 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2010 | 75 | 0.020 |
Why?
|
| Osteocytes | 1 | 2009 | 8 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 148 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 362 | 0.020 |
Why?
|
| Adipocytes | 1 | 2009 | 88 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 113 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2009 | 106 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 381 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 514 | 0.020 |
Why?
|
| Sphingosine | 1 | 2009 | 315 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 351 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1034 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2005 | 90 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 5300 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5731 | 0.010 |
Why?
|